State Street’s Liminatus Pharma LIMN Stock Holding History

State Street’s Portfolio LIMN Stock Details LIMN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-380	Closed	-$2.1K	–	4408
2026 Q2	$2.1K	Hold	380	–	–	﹤0.01%	4259
2026 Q1	$3.27K	Hold	380	–	–	﹤0.01%	4265
2025 Q4	$11.6K	Hold	380	–	–	﹤0.01%	4265
2025 Q3	$31.7K	Hold	380	–	–	﹤0.01%	4209
2025 Q2	$212K	Buy	+380	New	+$213K	﹤0.01%	3815

Other funds holding LIMN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Cheviot Value Management Beverly Hills, California $1.03B AUM 18.09% 1-Year Est. Return

State Street's LIMN Position: Q3 2026 in Review

State Street sold out of Liminatus Pharma (LIMN) in Q3 2026, closing a stake of 380 shares — an estimated $2.1K sold.

State Street first reported a position in LIMN in Q2 2025 and held it in 5 quarters. The position peaked at $212K in Q2 2025. 9 funds tracked by Wall St. Rank hold LIMN as of Q3 2026.

State Street reported no remaining Liminatus Pharma position as of Q3 2026 after selling out during the quarter.
State Street sold 380 Liminatus Pharma shares in Q3 2026, an estimated $2.1K.
State Street first reported a position in Liminatus Pharma in Q2 2025 and held it in 5 quarters.
State Street's Liminatus Pharma position peaked at $212K in Q2 2025.
9 funds tracked by Wall St. Rank held Liminatus Pharma as of Q3 2026.

Based on State Street's 13F filing for Q3 2026, filed 12 Nov 2026.